Key result
Low Naples Prognostic Score linked to ~58% lower mortality and less no-reflow during PCI for ACS.
Why the study?
Although the Naples Prognostic Score has emerged as a potential prognostic tool in cardiovascular conditions, no meta-analysis had pooled evidence to comprehensively assess its prognostic utility.
Does an elevated Naples Prognostic Score predict worse clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Does an elevated Naples Prognostic Score predict worse clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
An elevated Naples Prognostic Score is significantly associated with increased all-cause mortality and no-reflow phenomenon in ACS patients undergoing PCI, highlighting its potential as a simple, biomarker-based risk stratification tool.
Supports NPS for risk stratification in ACS-PCI; reinforces consensus on inflammatory-nutritional prognostic markers but needs prospective validation.
Background Naples Prognostic Score (NPS), a composite index incorporating inflammatory and nutritional markers, has emerged as a potential prognostic tool in various cardiovascular conditions; however, no meta‐analysis has yet pooled the available evidence to comprehensively assess its prognostic utility. Objectives To evaluate the association of NPS with clinical outcomes, including all‐cause mortality, in‐hospital mortality, no‐reflow (NR) phenomenon, and left ventricular ejection fraction (LVEF), in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Methods MEDLINE, Cochrane, and EMBASE databases were searched for studies comparing high and low NPS groups in ACS patients undergoing PCI. Random‐effects models were used to pool risk ratios (RR) for binary outcomes and mean differences (MD) for continuous outcomes. Heterogeneity was assessed with I² statistics. Statistical analyses were performed using Review Manager 5.4, and R, version 4.2.2. Results We included seven studies comprising 13 268 patients, with 5628 (42.4%) patients in the low NPS group. Low NPS was significantly associated with decreased all‐cause mortality (RR: 0.42; 95% CI: 0.32–0.55; I² = 48%) and decreased incidence of NR (RR: 0.60; 95% CI: 0.40–0.88; I² = 83%). Patients with low NPS also had higher LVEF (MD: −2.69%; 95% CI: −3.41 to −1.97; I² = 99%). No significant difference was observed in in‐hospital mortality (RR: 0.54; 95% CI: 0.28–1.05; I² = 94%). Conclusion In ACS patients undergoing PCI, elevated NPS was associated with worse clinical outcomes. These findings support the use of NPS as a practical, biomarker‐based tool for risk stratification in this population.
No takes yet. Share an insight, caveat, or question.
Özen et al. (2025) studied this question. Low Naples Prognostic Score was associated with reduced all-cause mortality (RR: 0.42) and lower incidence of no-reflow in ACS patients undergoing PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: